Background. Isolated locoregional recurrences (ILRRs) of breast cancer confer a significant risk for the development of distant metastasis. Management practices and second ILRR events in the Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial were investigated. Methods. In this study, 162 patients with ILRR were randomly assigned to receive postoperative chemotherapy or no chemotherapy. Descriptive statistics characterize outcomes according to local therapy and the influence of hormone receptor status on subsequent recurrences. Competing risk regression models, Kaplan-Meier estimates, and Cox proportional hazards models were used to evaluate associations between treatment, site of second recurrence, and outcome.
ILRR. For 15 patients, a second ILRR developed a median of 1.6 years (range 0.08-4.8 years) after ILRR. All second ILRRs occurred for patients with progesterone receptornegative ILRR. Death occurred for 7 (47 %) of 15 patients with a second ILRR and 19 (51 %) of 37 patients with a distant recurrence. As shown in the multivariable analysis, the significant predictors of survival after either a second ILRR or distant recurrence were chemotherapy for the primary cancer (hazard ratio [HR], 3.55; 95 % confidence interval [CI], 1.15-10.9; p = 0.03) and the interval (continuous) from the primary surgery (HR, 0.87; 95 % CI, 0.75-1.00; p = 0.05). Conclusions. Second ILRRs represented about one third of all recurrence events after ILRR, and all were PR-negative. These second ILRRs and distant metastases portend an unfavorable outcome.
Distant metastases after isolated locoregional recurrences (ILRR) of breast cancer occur in approximately 20-80 % of women, depending on whether the primary surgical treatment was mastectomy or breast-conserving surgery. [1] [2] [3] [4] [5] [6] [7] [8] Because most first ILRRs are operable, management of the recurrence is aimed at control of local disease via surgical excision and selective use of radiation therapy, depending on prior treatments. [9] [10] [11] [12] [13] Adjuvant therapies have long been demonstrated to decrease local recurrences as well as to improve survival. With the reporting of the Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial, the beneficial role of chemotherapy for ILRR is now clear. 14 Information is limited on the incidence of second isolated locoregional recurrence events after the treatment of an ILRR and the prognosis of patients who have a second ILRR. For example, local failure rates after salvage lumpectomy for ipsilateral breast tumor recurrences (IBTR) with or without repeat radiation have been reported exclusively in retrospective institutional series. Reported second IBTR rates range from 15 to 71 %. [15] [16] [17] [18] Survival after a second IBTR ranges from a median of 33 months 19 to a median of 80.7 % at 5 years. 20 Treatment of postmastectomy nodal or chest wall recurrences is associated with lasting local control of disease in about 50 % of cases, but no series has described outcomes after a second ILRR. 6, 21 The CALOR trial prospectively collected all relapse events occurring at any time, including a second ILRR. This report describes the rate of second ILRR, taking into consideration the management of the primary cancer and the management of the first ILRR, and examines outcomes after a second ILRR according to the hormone receptor status of the ILRR.
METHODS
The CALOR study (clinicaltrials.gov NCT00074152) was an international multicenter trial conducted from 2003 to 2010 by the International Breast Cancer Study Group (IBCSG), the Breast International Group (BIG), and the National Surgical Adjuvant Breast and Bowel Project (NSABP, now part of the NRG Oncology Portfolio).
14 A total of 162 patients who met the eligibility criteria were randomly assigned to receive chemotherapy or no chemotherapy after resection of ILRR. The eligibility criteria have been described previously. 14 The patients were stratified by hormone receptor status of ILRR, location of recurrence, and prior chemotherapy. Hormone receptor status was evaluated and defined per participating institution guidelines. Supraclavicular node recurrences were excluded. Details regarding the extent of treatment for the primary cancer were collected. Patients were not excluded from participating in this trial based on the characteristics of primary tumor therapy such as type of breast surgery, margin status, use of radiation therapy, and nodal staging procedures.
The CALOR study allowed investigators to choose chemotherapy agents while recommending the use of two or more drugs for 3-6 months. Endocrine therapy was required for ER-positive and/or PR-positive ILRR, and anti-HER2 therapy was recommended. Radiation therapy was recommended except after salvage mastectomy, and modifications were allowed for patients with previous irradiation.
After treatment of the ILRR, the sites of subsequent recurrence were recorded as local or regional (second ILRR), distant recurrence, second (nonbreast) malignancy, or contralateral breast cancer.
Statistical Analysis
The primary end point of the trial was disease-free survival (DFS), defined as the time from randomization to the first occurrence of an invasive breast cancer event, a second (nonbreast) primary cancer, or death. Descriptive statistics are used to characterize outcomes (site of the first subsequent recurrence as locoregional vs distant) according to local therapy and relation to hormone receptor status of the ILRR. Competing risk regression models 22 were used to account for the competing risks of a second ILRR or distant relapse as the first site of a subsequent recurrence. Kaplan-Meier estimates were used to evaluate survival after subsequent recurrence.
Univariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for association of the overall survival time after a subsequent recurrence with the site of the ILRR, the ER and PR status of the ILRR, receipt of adjuvant chemotherapy for the primary cancer, interval from primary surgery to ILRR (continuous) randomized treatment for ILRR (chemotherapy vs no chemotherapy), and site of the first subsequent recurrence (locoregional vs distant) for patients who had a second recurrence.
A multivariable Cox model was fitted for significant univariable factors and the site of the first subsequent recurrence. Analyses were retrospective and hypothesis generating. For the analyses, SAS 9.2 (SAS Institute, Cary, NC, USA) and R version 3 (The R Foundation for Statistical Computing, Vienna, Austria) were used. The ethics committees or institutional review boards of the participating institutions approved the trial according to local laws and regulations. All patients gave written informed consent, and the trial was conducted in compliance with the Helsinki Declaration.
RESULTS

Characteristics of ILRR
As previously published, the distribution of ILRR sites was similar across treatment arms. 14 The median interval between primary surgery and ILRR was 5.5 years. The median time to recurrence was 5.7 years (range 0.6-21.8 years) for the 89 patients with IBTRs and 5.4 years (range 0.3-31.6 years) for the 73 patients with ILRR recurrences outside the ipsilateral breast (chest wall, n = 53) or nodal region (n = 20). The predominant histology of the ILRR was ductal (n = 133) followed by lobular (n = 17) and mucinous (n = 3). Of the 123 recurrent cancers of known grade, 22 were grade 1, 50 were grade 2, and 51 were grade 3. For 108 patients (73 % of 148 known), the ILRR was 2 cm or smaller. The microscopic margins were positive in 14 cases (9 % of 162 cases).
Overall, 68 % (110/162) of the ILRRs were ER-positive, PR-positive, or both, although PR status was not reported for four recurrences. For 34 women, ILRRs occurred while they were receiving endocrine therapy or within 6 months after their completion of adjuvant treatment for the primary cancer. The ER status of the ILRR was discordant with the primary cancer in 21 cases (15 %). The ER status changed from ER-negative to ER-positive in six cases (4 %), and 15 ER-positive primary cancers (9 %) were classified as ER-negative ILRRs.
Expression of PR was discordant in 35 (26 %) of 137 primary cancers with known PR status. Whereas 8 (6 %) of these patients had a PR-negative primary and a PR-positive recurrence, 27 (20 %) had a PR-positive primary and a PRnegative recurrence. As reported, 93 patients had human epidermal growth factor receptor 2 (HER2) testing, but positive or negative results were not recorded. However, use of anti-HER2 treatments for the ILRR was recorded, and 10 patients received traztuzumab (4 in the no chemotherapy group and 6 in the chemotherapy group). Of the 15 patients with a second ILRR, 2 received trastuzumab for their second ILRR, both in the chemotherapy group. Figure 1 presents a summary of the trial participants in the CALOR trial with regard to their primary and ILRR treatments, starting with all 162 patients enrolled and ending with the 15 who experienced a second ILRR. Among the 98 women who had breast-conserving surgery, 90 (92 %) had undergone nodal staging as part of their initial therapy, as had 61 (95 %) of the 64 mastectomy-treated patients (Supplementary Table 1 ). Breast irradiation had been administered to 92 patients with breast-conserving surgery (BCS) (94 %), including a boost to the tumor bed for 41 patients (45 %). The ipsilateral breast was the site of the initial ILRR in 89 (91 %) of these 98 patients. The location of the IBTR in relation to the site of the primary cancer was not collected in the CALOR trial. Salvage mastectomy was performed for 73 (82 %) of the 89 IBTRs, and the remaining 16 patients had repeat breast-conserving surgery. Microscopically negative margins were achieved in all salvage mastectomy operations. Postoperative chest wall irradiation was used in only two of the salvage mastectomy-treated patients, and breast irradiation was used in 3 of the 16 patients with repeat breastconserving surgery, one of whom had not received breast irradiation previously.
Locoregional Treatment of ILRRs
Among the 64 patients with mastectomy-treated primary cancers, 52 (81 %) had mastectomy scar/chest wall ILRRs and 12 (19 %) had nodal recurrences. Among the 52 patients with mastectomy scar/chest wall ILRR, 10 had received prior postmastectomy irradiation. Resection of the ILRR achieved clear surgical margins in 50 of the patients (96 %), and 41 patients (79 %) received radiotherapy after resection of the ILRR, as prescribed by the protocol.
Second Locoregional Recurrences
A second ILRR developed as the site of the first recurrence after treatment of ILRR (Fig. 2a) for 15 patients (9 % of the study population), for 9 (12 %) of the 77 patients in the no-chemotherapy arm and for 6 (7 %) of the 85 patients in the chemotherapy arm of the study. The median interval from surgery for ILRR to surgery for the second ILRR for the 15 patients who experienced a second ILRR was 1.6 years (range 0.08-4.8 years). For 37 patients (23 %), distant recurrence developed as the site of the first recurrence after treatment of ILRR (4 with synchronous locoregional events: 3 local and 1 regional, not included among the 15 patients with a second ILRR) (Fig. 2a) . The median interval to a distant recurrence for these 37 patients was 1.1 years (range 0.1-6.8 years).
The sites of the 15 second ILRRs according to surgical treatment of ILRR are shown in Supplementary Table 2 . The incidences of second ILRR events after salvage mastectomy and after chest wall resection were similar (8.2 and 9.4 %, respectively). Likewise, the incidences of a second ILRR were 12.5 % after repeat breast-conserving surgery and 10 % after nodal resection.
Receptor Status and Second ILRR
Both ER and PR were reported for 158 of the 162 ILRRs and for all 15 second ILRRs. None of the 79 patients with PR-positive ILRR had a second ILRR (73 ER-positive/PRpositive and 6 ER-negative/PR-positive ILRRs), so all 15 patients with a second ILRR were PR-negative (6 ERpositive/PR-negative and 9 ER-negative/PR-negative ILRRs) ( Table 1) . Table 2 shows the impact of the randomized treatment group on subsequent DFS events according to ER and PR status of the ILRR. In the ER-negative/PR-negative subgroup, 3 (11 %) of 27 patients in the chemotherapy arm of the study had a second ILRR, whereas 6 (25 %) of 24 patients in the no-chemotherapy arm had a second ILRR. By contrast, in the ER-positive/PR-negaive subgroup, second ILRRs occurred for 3 (25 %) of 12 patients in the chemotherapy arm and 3 (19 %) of 16 patients in the nochemotherapy arm. Overall, the proportion of all subsequent DFS events after an ILRR was higher in the ER-positive/PR-negative cohort (15 of 28, 54 %) than in the ER-positive/PR-positive cohort (15 of 73, 21 %) ( Table 2 ). In contrast, 43 % of the patients with ER-negative/PR-negative ILRRs (22 of 51) experienced a subsequent DFS event. This exploratory analysis of ILRRs based on small subgroups suggests that ER-positive/PRnegative and ER-negative/PR-negative ILRRs have a poor prognosis.
Deaths After Subsequent Locoregional or Distant Recurrences
During a median follow-up period of 3.67 years after subsequent breast cancer recurrence, 7 (47 %) of 15 women with a second ILRR died (1 from a nonbreast event, CVA), compared with 19 (51 %) of 37 women who experienced distant recurrence events after ILRR (Fig. 2b) . The difference in survival from the time of the first subsequent recurrence after ILRR by site (distant vs second ILRR) was not statistically significant (multivariable HR 1.97; 95 % CI 0.73-5.29; p = 0.18; Table 3 , Fig. 2b) . Chemotherapy for the primary cancer and the interval from primary surgery to the ILRR were significant factors for survival after a recurrence subsequent to ILRR (Table 3) .
DISCUSSION
The CALOR trial tested the efficacy of systemic chemotherapy as an adjuvant treatment for patients with 14 This trial also provided an opportunity to evaluate the incidence, location, and prognosis of recurrences after the ILRR. Distant recurrences as the site of the first recurrence after treatment for an ILRR were more common than second ILRR events as the site of the first subsequent recurrence. Overall, the incidence of second ILRR events was similar whether the relapse occurred after chest wall resection, salvage mastectomy, or repeat breast lumpectomy.
All second ILRRs occurred among patients who had PRnegative ILRR with or without ER expression. Admittedly, the number of patients was quite small, but during the relatively short follow-up period of 5 years, the grouping of these recurrence in the PR-negative subgroup was striking. When it occurred, the time to a second ILRR was very short, underscoring the aggressive biology associated with these events that foreshadow poor outcomes. Our findings suggest that a subsequent recurrence occurring in a population receiving multimodality therapy for an ILRR is associated with poor outcomes. Specifically, after a median follow-up period of 3.7 years, the mortality after either a second ILRR or a distant metastasis was approximately 50 This study provides a perspective on local management of operable ILRR. As findings in the adjuvant and neoadjuvant settings have shown, systemic chemohormonal regimens improve local control of disease. 23, 24 Trial entry was predicated on the complete gross excision of the recurrent tumor. Although radiation therapy was recommended for all cases, only a handful received this treatment after salvage mastectomy or repeat breast-conserving surgery.
Salvage mastectomy was the most common operation used for women experiencing an IBTR. The remaining 18 % were treated by repeat breast conservation, with 19 % undergoing re-radiation. Notably, the majority of the patients achieved very good local control after treatment of ILRR, with comparable rates for the second ILRR (8.2 % of the salvage mastectomy population and 12.5 % in the repeat breast-conserving surgery group). The in-breast recurrences after repeat breast-conserving surgery ranged between 7 and 38 % (36-to 120-month follow-up period). 11, 18 Gentilini et al. 18 found a higher second local failure rate than in our trial (27 % of 161 IBTR cases treated by repeat breast conservation).
Re-radiation of the breast was reported for a minority of patients (3 of 16) in our study. Publications of nonrandomized series report its feasibility and higher local control rates with additional radiation, [25] [26] [27] but even with restricted volumes such as brachytherapy or intraoperative radiation therapy, greater tissue/skin toxicity is reported. 28 Forthcoming data on the prospective phase 2 trial involving repeat lumpectomy with three-dimensional (3D)-conformal partial breast re-radiation to 45 Gy will provide additional information on the efficacy of this approach (RTOG trial 1014). Locoregional recurrence (LRR) events are significantly associated with a higher risk for the development of distant metastasis. 3, 4 Tanis et al. 29 analyzed late ILRRs across European Organisation for Research and Treatment of Cancer (EORTC) trials. Even 10 years after breast-conserving treatment for a primary cancer occurrence, an ILRR was a highly unfavorable, independent prognostic indicator associated with distant metastases. In two retrospective analyses of lumpectomy-treated patients in five node-positive and five node-negative randomized trials conducted by the NSABP, women who experienced other LRRs had worse DFS and OS than those with IBTR. 5, 7 These differences were not apparent in the CALOR trial, in which patient entry was influenced by investigator and prospective participant considerations.
The debate on the biologic significance of ILRR continues. Clearly, the size of recurrence is not a significant determinant of subsequent prognoses. In our study, 67 % of ILRRs were 2 cm or smaller, and in the absence of adjuvant chemotherapy, the 5-year DFS was 69 % for ERpositive tumors and 35 % for ER-negative tumors.
14 One perspective is centered on optimizing local therapy as a means of decreasing distant metastases. 30 Lowering LRR with the use of adjuvant radiotherapy demonstrates improvements in 15-year DFS and survival in prospective randomized trials. 31 However, for many patients, local failures are important indicators of a poorer prognosis and denote biologically resistant disease for those who received optimal first-line adjuvant treatments.
Few clinical trials have addressed the questions of persistent locoregional control after the treatment of an ILRR. During a median follow-up period of 4.9 years, the overall results of the CALOR trial showed that chemotherapy significantly prolonged DFS (HR 0.59; 95 % CI 0.35-0.99; p = 0.046) and OS (HR 0.41; 95 % CI 0.19-0.89; p = 0.02).
14 Most dramatic was the effect seen in the subgroup of ER-negative/PR-negative patients, whose risk of distant disease was reduced by 68 % and death by 57 %. 14 The current analysis also suggests that the administration of adjuvant chemotherapy at the time of ILRR may reduce second ILRR as well, and that subsequent recurrences, whether local or distant, occur early and portend a high likelihood of death. This poor outcome after second ILRR should be taken into account when such recurrences are treated.
